{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:06:42Z","timestamp":1790165202549,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum AB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rpth.2026.106871","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:29:02Z","timestamp":1784302142000},"page":"106871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Avatrombopag in thrombopoietin receptor agonist-na\u00efve patients with immune thrombocytopenia: real-world treatment patterns and clinical outcomes from the REAL-AVA 3.0 study"],"prefix":"10.1016","volume":"10","author":[{"given":"Sandhya","family":"Panch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiola","family":"Oladapo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kolodny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7691-8027","authenticated-orcid":false,"given":"Michael","family":"Vredenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prathamesh","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106871_bib1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/JBM.S259101","article-title":"Management of adult patients with immune thrombocytopenia (ITP): a review on current guidance and experience from clinical practice","volume":"12","author":"Song","year":"2021","journal-title":"J Blood Med"},{"key":"10.1016\/j.rpth.2026.106871_bib2","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106871_bib3","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106871_bib4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13696998.2019.1669329","article-title":"Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis","volume":"23","author":"Weycker","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.rpth.2026.106871_bib5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/17474086.2018.1548930","article-title":"Health-related quality of life in adult primary immune thrombocytopenia","volume":"11","author":"Sest\u00f8l","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2026.106871_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221130335","article-title":"Patient and physician perspectives in the management of immune thrombocytopenia in Iran: responses from the ITP World Impact Survey (I-WISh)","volume":"29","author":"Eshghi","year":"2023","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106871_bib7","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106871_bib8","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106871_bib9","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.2146\/news080078","article-title":"FDA approves thrombopoiesis-stimulating agent","volume":"65","author":"Thompson","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.rpth.2026.106871_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.106871_bib11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.106871_bib12","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106871_bib13","first-page":"1171","article-title":"Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura","volume":"23","author":"Dmytrijuk","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.rpth.2026.106871_bib14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106871_bib15","series-title":"DOPTELET (avatrombopag) [package insert]","year":"2024"},{"key":"10.1016\/j.rpth.2026.106871_bib16","series-title":"NPLATE (romiplostim) [package insert]","year":"2025"},{"key":"10.1016\/j.rpth.2026.106871_bib17","series-title":"PROMACTA (eltrombopag) [package insert]","year":"2025"},{"key":"10.1016\/j.rpth.2026.106871_bib18","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","article-title":"Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists","volume":"81","author":"Gilreath","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.rpth.2026.106871_bib19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106871_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bjh.18081","article-title":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study","volume":"197","author":"Al-Samkari","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106871_bib21","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/bloodadvances.2024015635","article-title":"Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA","volume":"9","author":"Tarantino","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106871_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231179856","article-title":"Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study","volume":"14","author":"Oladapo","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2026.106871_bib23","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/ajh.27498","article-title":"Avatrombopag in immune thrombocytopenia: a real-world study of the Spanish ITP Group (GEPTI)","volume":"99","author":"Pascual-Izquierdo","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2026.106871_bib24","author":"Levy"},{"key":"10.1016\/j.rpth.2026.106871_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100134","article-title":"Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia","volume":"7","author":"Al-Samkari","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106871_bib26","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjh.19975","article-title":"Avatrombopag in adults with immune thrombocytopenia: a multicentre real-life observational study in Madrid, Spain (AVAMAD study)","volume":"206","author":"Pascual-Izquierdo","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106871_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ajh.27080","article-title":"Avatrombopag for adults with early versus chronic immune thrombocytopenia","volume":"99","author":"Virk","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2026.106871_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102158","article-title":"Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China","volume":"7","author":"Mei","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106871_bib29","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/bloodadvances.2023012541","article-title":"The 2022 review of the 2019 American Society of Hematology Guidelines on immune thrombocytopenia","volume":"8","author":"Neunert","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106871_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.glmedi.2025.100200","article-title":"Availability and completeness of real-world data in United States community oncology\/hematology practices regarding chimeric antigen receptor (CAR T)-cell therapy for relapsed\/refractory diffuse large B-cell lymphoma","volume":"6","author":"Porter","year":"2025","journal-title":"J Med Surg Public Health"},{"key":"10.1016\/j.rpth.2026.106871_bib31","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","article-title":"Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents","volume":"116","author":"Bao","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106871_bib32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.2024025707","article-title":"Long-term follow-up of the STOPAGO study","volume":"145","author":"Cottu","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106871_bib33","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjh.17334","article-title":"Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study","volume":"193","author":"Lucchini","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106871_bib34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.13827","article-title":"Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study","volume":"172","author":"Newland","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106871_bib35","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.3324\/haematol.2016.151886","article-title":"Remissions after long-term use of romiplostim for immune thrombocytopenia","volume":"101","author":"Marshall","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106871_bib36","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/bjh.19800","article-title":"Real-world evidence of avatrombopag for the treatment of immune thrombocytopenia intolerant or ineffective to eltrombopag\/hetrombopag","volume":"205","author":"Tian","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106871_bib37","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/bjh.18908","article-title":"A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP","volume":"202","author":"Tarantino","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106871_bib38","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2169\/internalmedicine.51.7106","article-title":"Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim","volume":"51","author":"Shinohara","year":"2012","journal-title":"Intern Med"},{"key":"10.1016\/j.rpth.2026.106871_bib40","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","article-title":"A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia","volume":"123","author":"Bussel","year":"2014","journal-title":"Blood"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:50:07Z","timestamp":1790164207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2475037926035296"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106871","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avatrombopag in thrombopoietin receptor agonist-na\u00efve patients with immune thrombocytopenia: real-world treatment patterns and clinical outcomes from the REAL-AVA 3.0 study","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106871"}}